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Maria Söderlund-Venermo, and Klaus Hedman
To determine the prevalence of parvovirus 4 infection 
and its clinical and sociodemographic correlations in Fin-
land, we used virus-like particle–based serodiagnostic pro-
cedures (immunoglobulin [Ig] G, IgM, and IgG avidity) and 
PCR. We found 2 persons with parvovirus 4 primary infec-
tion who had mild or asymptomatic clinical features among 
hepatitis C virus–infected injection drug users.
A new member of family Parvoviridae, human par-vovirus 4 (PARV4), was identifi ed in plasma of an 
injection drug user (IDU) with unexplained fatigue, head-
aches, fever, night sweats, nausea, and diarrhea (1). In 
PCR studies of blood and postmortem tissues, virus was 
detected mainly in persons with histories of injection drug 
use (2–5). A recent PARV4 immunoglobulin (Ig) G study 
also showed higher prevalence of antibodies to PARV4 in 
IDUs and HIV-positive persons who had hemophilia than 
in HIV-positive men who have sex with men (6). The clini-
cal role of this virus is unknown.
We report virus-like particle–based comprehensive 
serodiagnosis for PARV4 and determine its occurrence in 
Finland in 3 diverse population groups. In the highest prev-
alence group, we comparatively analyzed PARV4 IgG–
positive and IgG–negative persons for sociodemographic 
and behavioral background factors and symptoms by using 
an HIV risk factor database (7).
The Study
Group 1 (low risk) comprised 115 university students 
(1 serum sample/student). Group 2 (high risk) comprised 
78 HIV IgG–positive IDUs from the Helsinki Cohort Study 
(8) (151 plasma samples, 1–7 samples/person). Group 3 
(high risk) comprised 200 hepatitis C virus (HCV) IgG–
positive patients (1 sample/person). Informed consent 
was obtained from persons in groups 1 and 2 and from 
2 patients with primary infections in group 3. The study 
was reviewed and approved by the Helsinki University 
Central Hospital Ethics Committee (#281/13/03/01/09 
and #469/2001).
Four genomic regions of open reading frame 2 of 
PARV4 genotype 1 (AY622943) were cloned for bac-
ulovirus expression by using PARV4 PCR–positive 
plasma (1) as initial template. The clone with nt region 
3137–5122 (AY622943) and infectivity was construct-
ed with primers PARV4EcoRI_3137: 5′-TATGAATT
CATGATTGAGCATGGGG-3′ and PARV4EagI_5122: 
5′-TACGGCCGTTACAGCAAATGAGAATAA-3′.
Protein expression and virus-like particle purifi cation 
were conducted as for human bocavirus (HBoV) (9). So-
dium dodecyl sulfate–polyacrylamide gel electrophoresis 
identifi ed a 73-kDa protein (Figure 1, panel A), which was 
immunoreactive by Western blotting (10) with 5 known 
PARV4 IgG–positive serum samples (6) but not with nega-
tive serum samples (Figure 1, panel B). Electron micros-
copy showed spherical particles ≈25 nm in diameter (Fig-
ure 1, panel C) that resembled those seen in vivo (11). The 
capsid protein region is 109 aa longer (N terminally) than 
that reported by Sharp et al. (6); both constructs assembled 
into capsids.
PARV4 IgG enzyme immunoassay (EIA) was con-
ducted as for HBoV (9). Specifi c results were obtained by 
subtracting antigen-free background levels. For IgM EIA, a 
μ-capture format was used (9). IgG and IgM cutoff values, 
obtained from group 1 absorbances (mean + 4 × SD), were 
0.141 and 0.205, respectively. IgG-avidity EIA was con-
ducted as for HBoV (method A) (12); cutoff values for high 
and low avidity were 25% and 15%, respectively.
None of the 115 students (group 1) were PARV4 IgG 
positive, and 1 (0.9%) of 115 was weakly IgM positive 
(Figure 2, panel A). Sixty-one (78.2%) of 78 HIV-infected 
patients (group 2) were IgG positive, and 4 (5.1%) of 78 
were IgM positive (Figure 2, panel B). Sixty-nine (34.5%) 
of 200 HCV-infected patients (group 3) were IgG positive, 
and 3 (1.5%) of 200 were IgM positive (Figure 2, panel C). 
Previous samples were available for 2 of the IgM-positive 
patients (A and B) in group 3. These samples showed sero-
conversion for IgG and an increase in IgG (Table 1).
PARV4 IgG avidity was determined in all persistently 
(>1 year) IgG-positive persons in group 2 (n = 29). Twen-
ty-eight persons showed high IgG avidity, and 1 showed 
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borderline IgG avidity. All 4 IgG-positive persons had 
high-avidity IgG, which indicated previous immunity.
In group 3, a second sample from patient A, who 
showed seroconversion for IgG showed borderline IgG 
avidity. Patient B showed low IgG avidity in both samples 
(Table 1).
Groups 2 and 3 were also analyzed for PARV4 DNA 
by qualitative PCR (13) as modifi ed (94°C for 10 min; 45 
cycles at 94°C for 20s, 51°C or 56°C for 20s, and 72°C 
for 20s; and extension at 72°C for 7 min). Amplicons were 
subjected to electrophoresis and sequenced. In group 2, all 
151 serum samples were PCR negative. In group 3, two 
patients (A and B) were PCR positive (Table 1).
PARV4 IgG–positive and IgG–negative IDUs (group 
2) were compared for demographic and clinical charac-
teristics. PARV4 IgG–positive persons reported more in-
jection of drugs, persistent (>10 y) injection, and lending 
of injection equipment (Table 2). They also had a more 
frequent history of imprisonment and unemployment and 
were less educated. No differences were seen between 
PARV4 IgG–positive and IgG–negative persons with any 
symptoms (fever, tiredness, nocturnal sweating, cough, di-
arrhea, shortness of breath, swallowing complaints, muscle 
weakness, dizziness, skin abscesses or herpetic lesions, 
loss of eyesight, or headache) during 6 months before be-
ing interviewed.
Conclusions
We developed IgG-, IgM-, and IgG-avidity–based 
PARV4 serodiagnostic procedures; studied high-preva-
lence cohorts by PCR; and analyzed HIV-infected IDUs 
for demographic and clinical correlations with PARV4 
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Figure 1. Parvovirus 4 (PARV4) virus-like particle (VLP) expression and immunoreactivity, Finland. A) Sodium dodecyl sulfate–
polyacrylamide gel electrophoresis of PARV4-like particles in Spodoptera frugiperda armyworm (Sf)9 cells (lane 1), purifi ed VLPs (lane 
2), and uninfected Sf9 cells (lane 3). B) Western blotting with PARV4 immunoglobulin (Ig) G–positive serum (lanes 1, 3, and 4) or PARV4 
IgG–negative serum (lane 2). Lanes 1 and 2, purifi ed VLPs as antigen; lane 3, Sf9 cells expressing VLPs; lane 4, Sf9 cells expressing 
glutathione-S-transferase control antigen; lanes M, molecular mass marker. Arrows in panels A and B indicate the PARV4 capsid protein. 
C) Electron micrograph of purifi ed VLPs. Scale bar = 200 nm.
Figure 2. Parvovirus 4 (PARV4) enzyme immunoassay (EIA) results, Finland. Red dots, immunoglobulin (Ig) M; ×, IgG. Upper dashed 
line indicates IgM cutoff value (0.205), and lower dashed line indicates IgG cutoff value (0.141). A) Group 1: 115 university students (1 
serum sample/person); none positive for PARV4 IgG, and 1 positive for PARV4 IgM. B) Group 2: 78 HIV-infected injection drug users (151 
serum samples [1–7 samples/person]). Prevalences of PARV4 IgG and IgM were 78.2% (61/78) and 5.1% (4/78), respectively. C) Group 
3: 200 hepatitis C virus–infected patients (1 sample/person). Prevalences of PARV4 IgG and IgM were 34.5% (69/200) and 1.5% (3/200), 
respectively.
Primary Infections with PARV4, Finland
IgG positivity. Among healthy university students, none 
had PARV4 IgG, which is consistent with low baseline 
IgG prevalences of 0% and 2.8% for another EIA (6). The 
PARV4 IgG seroprevalence of 78% among HIV-infected 
IDUs represents a high incidence of PARV4, which refl ects 
the lengthy history of drug use among socially marginal-
ized IDUs during an HIV outbreak in Finland (7).
Two HCV-infected patients had PARV4 primary infec-
tions, as shown by increasing IgG levels, detectable IgM, 
low or borderline IgG avidity, and viral DNA in serum. 
These 4 fi ndings are presented as diagnostic criteria for 
PARV4 primary infection. As estimated by known kinetics 
of B19 virus diagnostics (14), these 2 PARV4 infections 
probably occurred in 2005. During that time, neither pa-
tient had contacted local healthcare providers. Conversely, 
these 2 patients used intravenous drugs daily, and might not 
have sought medical care unless they were severely ill.
Because PARV4 IgG seroprevalence in group 1 was 
0% in this study, in contrast to prevalences of 60% for B19 
(12) and 96% for HBoV (9) in the same students, serologic 
cross-reactivity between PARV4 and the other human par-
voviruses appears highly unlikely. Amino acid sequence 
similarity is <30% between B19 and PARV4 and ≈40% 
between HBoV and PARV4.
PCR-negative results for group 2, including 4 patients 
who were IgM positive, are evidence against viremic pri-
mary, chronic, and recurrent PARV4 infections. However, 
because of the relatively low sensitivity of this PCR, the 
data do not rule out low levels of viral DNA in blood.
Analysis of HIV-infected IDUs supports the view that 
in northern Europe PARV4 is primarily a blood-borne vi-
rus. No differences were seen for factors related to sexual 
activity. However, our sample size was too small to make 
this conclusion. In a recent PCR study, PARV4 genotype 
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Table 1. Virologic findings for PARV4 primary infections in 2 patients, Finland* 
Patient Date of sampling IgG EIA absorbance IgM EIA absorbance PCR IgG avidity, % 
A 2004 Sep 8 0.016 0.051 – ND 
2006 Mar 14 2.873 0.218 + 17.7
B 2006 Mar 13 0.950 1.461 + 8.9
2006 Apr 6 1.946 0.661 + 10.1
*PARV4, parvovirus 4; Ig, immunoglobulin; EIA, enzyme inmmunoassay; –, negative; ND, not determined; +, positive. 
Table 2. Characteristics of PARV4 IgG–positive and IgG–negative HIV-infected injection drug users, Finland* 
Characteristic IgG positive, n = 61 IgG negative, n = 17 p value† 
Age, y, median (range) 35 (17–61) 31 (21–55) 0.069 
Male sex 44/61 (72) 12/17 (71) 1.000 
Main drug was amphetamine‡ 38/61 (62) 10/17 (59) 0.786 
Duration of injection, y, median (range) 10 (0–36) 7 (0–30) 0.259 
Duration of injection >10 y 45/59 (76) 7/17 (44) 0.029 
History of imprisonment 49/61 (80) 9/17 (53) 0.031 
Education <9 y 52/59 (88) 10/17 (59) 0.011 
HCV antibody positive 59/60 (98) 14/15 (93) 0.362 
HBsAg positive 3/61 (5) 3/17 (18) 0.114 
HBc IgG positive 46/60 (77) 9/17 (56) 0.124 
Used antiretroviral therapy§ 29/61 (48) 4/17 (24) 0.099 
CD4 cell count/μL, median§ 303 323 0.168 
Present situation 
 Unstable living conditions (no permanent address) 35/59 (60) 5/15 (33) 0.088 
 Employed‡ 0/53 (0) 3/16 (19) 0.009 
Risk behavior 
 Loaned needles or syringes 49/59 (83) 9/16 (56) 0.040 
 Borrowed needles or syringes 56/58 (97) 15/16 (94) 0.524 
 Had sexually transmitted diseases 37/57 (65) 7/17 (41) 0.097 
 Had commercial sex 18/61 (30) 8/15 (53) 0.127 
Risk behavior past 6 mo 
 Used drugs 48/61 (79) 8/17 (47) 0.016 
 Used injection drugs 46/61 (75) 8/17 (47) 0.037 
 Used condoms inconsistently 25/61 (41) 7/16 (44) 1.000 
 Had >2 sex partners 16/61 (26) 7/17 (41) 0.244 
*Values are no. positive/no. tested (%) unless otherwise indicated. PARV4, parvovirus 4; Ig, immunoglobulin; HCV, hepatitis C virus; HBsAg, hepatitis B 
surface antigen; HBc, hepatitis B core antigen; 
†By Fisher exact test or Mann-Whitney U test. Values in boldface are significant. 
‡At the time of interview. 
§Closest to the sampling for PARV4 tests. 
3 was commonly found among infants in West Africa, and 
there was no evidence of parenteral exposure (15).
Using comprehensive serodiagnosis, we showed that 
PARV4 is ubiquitously present in IDUs in Finland and de-
tected primary infections in 2 patients who had a full spec-
trum of diagnostic fi ndings. Neither of these had sought 
medical help, which suggested that their primary infections 
may have been clinically mild or asymptomatic.
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